Biosynthetic cannabinoids (CBD & THC)

01Overview and value chain

Markers: [EC: Controlled Substances & Novel Food regulation | OECD: industrial-biotech | Regulator: FDA (US), EMA (EU), NMPA (CN)]

Biosynthetic cannabinoid production replaces field-grown hemp with engineered microbial fermentation or chemo-enzymatic synthesis to manufacture CBD, THC and rarer cannabinoids (CBG, CBDV, THCV) as pharmaceutical-grade platform molecules. In the US, the DEA’s 2024 rescheduling of cannabis from Schedule I to Schedule III removed decades-old research restrictions and accelerated venture investment into precision cannabinoid biology; Jazz Pharmaceuticals’ plant-derived CBD drug Epidiolex reported 15% year-on-year sales growth in Q1 2026 within a company-wide revenue increase of 19%. Engineered-yeast platforms are the fastest-growing production route: Willow Biosciences has engineered a quadruple-mutant prenyltransferase (NphB variant V49W/S214H/A232S/Y288P) for efficient cannabigerolic acid (CBGA) synthesis and signed a multi-product API licensing and manufacturing partnership with Laurus Labs, while Ginkgo Bioworks holds patent filings on recombinant-cell biosynthesis of cannabinoids and their precursors. Purity standards are stringent throughout: DEA-licensed bulk manufacturers such as Purisys operate under Schedule I-V handling permits and GMP/DMF certification to supply pharmaceutical-grade isolates.

The key directions of biosynthetic cannabinoids are:

1. Precision fermentation (Precision Fermentation): engineering yeast (commonly Saccharomyces cerevisiae) to express the full cannabinoid biosynthesis pathway — hexanoyl-CoA, olivetolic acid synthase/cyclase, and a prenyltransferase — directly from simple sugars, without cultivating cannabis plants.
2. Rare-cannabinoid access (Rare-Cannabinoid Access): producing minor cannabinoids (CBG, CBC, THCV, CBDV) that occur at trace levels in the plant but can be made at scale via selective enzymatic cyclization of the common CBGA precursor.
3. Chemo-enzymatic and chemical synthesis (Chemo-Enzymatic Synthesis): acid-catalyzed and enzyme-assisted routes to ultra-high-purity CBD/THC isolates for DEA-licensed bulk manufacturers supplying pharmaceutical formulators.
4. Purification engineering (Purification Engineering): supercritical CO2 extraction and centrifugal partition chromatography to separate structurally similar cannabinoids to pharmacopeial purity without residual solvent.

Sectoral value chain

[Feedstock/Strain] ──> [Synbio & Biosynthesis] ──> [Extraction & Purification] ──> [B2B Distribution]
                                  │
                          (GMP validation)
                                  │
                                  ▼
[End Markets] <─── [Regulatory Certification] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Prenyltransferase engineering: directed evolution of prenyltransferase enzymes (e.g., engineered NphB variants) to efficiently couple geranyl pyrophosphate to olivetolic acid, forming the universal CBGA precursor.
• Supercritical CO2 extraction (SC-CO2): CO2 held above ~73 bar and 31°C behaves as a solvent with gas-like penetration, selectively pulling lipophilic cannabinoids from biomass while leaving chlorophyll and heavy metals behind.
• Centrifugal partition chromatography (CPC): solid-support-free liquid-liquid chromatography that separates structurally close cannabinoids (e.g., minor CBG from bulk CBD) to fraction purities above 99.8%.

02US

The US leads both plant-derived and biosynthetic cannabinoid commercialization, propelled by the DEA’s 2024 Schedule III reclassification and a wave of venture-funded precision-biology startups.

DEA rescheduling, precision-fermentation startups, DEA-licensed bulk manufacturing

• Jazz Pharmaceuticals: markets Epidiolex, the FDA-approved plant-derived CBD drug for severe childhood epilepsy, reporting 15% year-on-year sales growth in Q1 2026 as part of 19% overall company revenue growth.
• Ginkgo Bioworks: holds patent filings covering recombinant-cell biosynthesis of cannabinoids and cannabinoid precursors, applying its synthetic-biology foundry model to the sector.
• Purisys: a DEA-licensed (Schedule I-V) bulk manufacturer of ultra-high-purity CBD/THC isolates under FDA Drug Master File and GMP certification, recently acquired by Siegfried, a global pharmaceutical CDMO.

03CN

China dominates raw industrial-hemp cultivation and export rather than cannabinoid biosynthesis — no dedicated Chinese biosynthetic-cannabinoid producer was confirmed via live sourcing for this article.

industrial hemp cultivation scale, cosmetic/textile export, domestic sales restriction

• Cultivation scale: China grows a large share of the world’s industrial hemp, concentrated in Yunnan and Heilongjiang provinces, primarily for fiber, seed-oil and cosmetic-extract export rather than domestic CBD sales, which remain tightly restricted.
• Export orientation: hemp-derived CBD extracts produced under state oversight are exported to Asian and EU cosmetics markets rather than sold as pharmaceutical or wellness products domestically.
• NMPA posture: China has not opened an NMPA pathway for cannabinoid pharmaceuticals or wellness products, keeping the domestic market oriented toward fiber and industrial hemp rather than platform-molecule biosynthesis.

04EU

The EU’s cannabinoid economy centers on pharmaceutical integration and a Novel Food compliance pathway for CBD, rather than domestic biosynthesis capacity.

Novel Food certification, pharmaceutical integration, GMP extraction capacity

• Novel Food status for CBD: EFSA classifies non-decarboxylated CBD as a Novel Food, requiring a full toxicological dossier before producers can sell it in functional beverages, adaptogenic blends or sports-nutrition products.
• Jazz Pharmaceuticals (Ireland): headquartered in Dublin, Jazz markets Epidiolex across EU markets under EMA approval for severe childhood epilepsy syndromes.
• GMP extraction capacity: German and Polish facilities operate GMP-certified supercritical-CO2 extraction lines, supplying pharmaceutical-grade cannabinoid intermediates to the EU market.

05Leading companies and research institutes

06Tech stack and innovations

The cannabinoid biosynthesis stack pairs synthetic-biology pathway engineering with pharmaceutical-grade downstream purification.

1. Heterologous biosynthesis pathway (yeast):
   • Genes for hexanoyl-CoA synthesis, olivetolic acid synthase/cyclase, and a prenyltransferase are assembled in S. cerevisiae to produce cannabigerolic acid (CBGA), the universal precursor, directly from sugar.
   • Downstream synthases (THCA-, CBDA-, CBCA-synthase) selectively cyclize CBGA into the target cannabinoid acid, which mild heat then decarboxylates to its neutral, active form.
2. Supercritical CO2 extraction:
   • Operating in the 250-300 bar range at controlled temperature, SC-CO2 selectively dissolves lipophilic cannabinoids and terpenes while excluding polar chlorophyll, sugars and heavy metals.
   • Winterization in cold ethanol then precipitates plant waxes, which are removed by filtration before solvent recovery.
3. Centrifugal partition chromatography and crystallization:
   • CPC achieves continuous separation of closely related cannabinoids (e.g., minor CBG from bulk CBD) without a solid stationary phase, reaching fraction purities above 99.8%.
   • Controlled-rate cooling crystallization (avoiding amorphous precipitation) yields pharmacopeial-grade crystalline isolate, typically specified above 99.5% purity with THC below 0.01%.

07Value chains and production pipelines

Industrial pipeline of crystalline CBD isolate production (US FDA GMP)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Biomass prep &          │ ───> │ 2. Supercritical CO2      │
│    decarboxylation         │      │    extraction              │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Rotary evaporation &    │ <─── │ 3. Winterization           │
│    solvent recovery        │      │    (wax removal)           │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Crystallization &       │ ───> │ 6. HPLC testing & GMP     │
│    isolation                │      │    packaging               │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Biomass preparation and decarboxylation

Dried hemp biomass (or fermentation-derived cannabinoid-acid biomass) is milled to ~2mm particle size and heated in a vacuum oven at roughly 110°C for about 4 hours, converting acidic CBDA into its neutral, bioactive CBD form.

Stage 2: Supercritical CO2 extraction

Liquid CO2 above its critical point (roughly 280 bar, 45°C) selectively dissolves lipophilic cannabinoids into a crude resin containing about 50-60% CBD, while leaving behind polar plant matter.

Stage 3: Winterization (wax removal)

The crude resin is dissolved in anhydrous ethanol and frozen (around -40°C) for about 24 hours, precipitating plant waxes that are removed by filtration.

Stage 4: Rotary evaporation and solvent recovery

The winterized ethanol solution is distilled under reduced pressure (~100 mbar, 40°C) to recover ethanol for reuse and yield a purified distillate oil.

Stage 5: Crystallization and isolation

The distillate is dissolved in warm hexane/pentane and cooled in a controlled manner (roughly 1°C per hour) to precipitate CBD crystals, which are separated by centrifuge and vacuum-dried.

Stage 6: HPLC testing and GMP packaging

Dried crystals are milled to a micronized powder (targeting >99.5% CBD purity, <0.01% THC), tested by HPLC/ICP-MS for heavy metals and pesticide residues, then packaged under GMP for pharmaceutical customers.